Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Semax

ACTH(4-10) analogue, Heptapeptide SEMAX

Quick Stats
Studies 172
Trials 37
Score 2
2002 pubmed

[Neuroprotective effects of semax in MPTP-induced disturbances of brain dopamine system].

Levitskaia. N G NG; Sebentsova. E A EA; Andreeva. L A LA; Alfeeva. L Iu LIu; Kamenskiĭ. A A AA; Miasoedov. N F NF

Key Findings

  • MPTP toxin reduced motor activity and increased anxiety in rats.
  • Daily intranasal semax (0.2 mg/kg) lessened these behavioral changes.
  • The protective effect may come from semax’s influence on dopamine pathways and its general neuroprotective properties.

Practical Outcomes

  • For biohackers, this suggests semax could have neuroprotective potential, but the evidence is limited to animal models. No human dosing or safety data are available, so it’s not ready for direct self‑experimentation. Keep an eye on future clinical research before considering any protocols.

Summary

In rats, a tiny peptide called semax given through the nose helped protect brain dopamine cells from damage caused by a toxin, keeping the animals more active and less anxious.

Abstract

Effects of an ACTH (4-10) analogue Semax (MEHFPGP) on behaviour of white rats with MPTP-induced disturbances of brain DA-system have been studied. It was shown that MPTP administration (25 mg/kg) reduced motor activity and auhmented the anxiety level in rats. Semax administration (daily intranasal 0.2 mg/kg) attenuated behaviour disturbances induced by neurotoxin. The observed protective action of Semax in rats with MFTP-induced DA system disturbances may be due to both its modulating influence on the brain DA system and peptide neuroprotective effects.

Study Information

Provider

pubmed

Year

2002